陈绿云, 殷佳慧, 杨岚寓, 杨光忠, 耿传营, 刘念, 菅原, 刘爱军. SUDOSCAN检测快速有效评估硼替佐米致周围神经病变[J]. 中国肿瘤临床, 2023, 50(8): 398-402. DOI: 10.12354/j.issn.1000-8179.2023.20230066
引用本文: 陈绿云, 殷佳慧, 杨岚寓, 杨光忠, 耿传营, 刘念, 菅原, 刘爱军. SUDOSCAN检测快速有效评估硼替佐米致周围神经病变[J]. 中国肿瘤临床, 2023, 50(8): 398-402. DOI: 10.12354/j.issn.1000-8179.2023.20230066
shu
Lvyun Chen, Jiahui Yin, Lanyu Yang, Guangzhong Yang, Chuanying Geng, Nian Liu, Yuan Jian, Aijun Liu. SUDOSCAN: a tool for quick and effective evaluation of bortezomib-induced peripheral neuropathy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(8): 398-402. DOI: 10.12354/j.issn.1000-8179.2023.20230066
Citation: Lvyun Chen, Jiahui Yin, Lanyu Yang, Guangzhong Yang, Chuanying Geng, Nian Liu, Yuan Jian, Aijun Liu. SUDOSCAN: a tool for quick and effective evaluation of bortezomib-induced peripheral neuropathy[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 50(8): 398-402. DOI: 10.12354/j.issn.1000-8179.2023.20230066
shu

SUDOSCAN检测快速有效评估硼替佐米致周围神经病变

SUDOSCAN: a tool for quick and effective evaluation of bortezomib-induced peripheral neuropathy

    摘要
  • 摘要:
      目的  本研究旨在探索SUDOSCAN检测（一种外周自主神经功能检测工具）对硼替佐米致周围神经病变（bortezomib-induced peripheral neuropathy，BIPN）的评估效果。
      方法  以2021年7月至2022年10月首都医科大学附属北京朝阳医院血液科确诊的86例多发性骨髓瘤（multiple myeloma，MM）患者作为研究对象，另外选取30例无肿瘤史及化疗药物接触史的患者作对照，所有患者均接受了SUDOSCAN皮肤电导率（ESC值）检测，同时与总神经病变评分临床版（TNSc）、美国国立癌症研究所常见毒性分级标准（NCI-CTC）分级评分对比，并对试验组患者进行了评估所需时间比较。
      结果  试验组患者手部、足部ESC值比对照组明显降低（手部：56.4 μs vs. 76.5 μs，P<0.001；足部：47.5 μs vs. 78.0 μs，P<0.001）；SODUSCAN 评估患者足部ESC值与TNSc评分呈显著负相关（r=−0.403，P<0.001）、与NCI-CTC等级无明显相关性(r=−0.227，P=0.051)；NCI-CTC等级与TNSc评分呈显著正相关(r=0.591，P<0.001)。SUDOSCAN检测所需中位评估时间与NCI-CTC等级相近（均为2.4 min），TNSc评分所需中位评估时间最长（13.4 min）。
      结论  目前，BIPN缺乏准确、高效评估方式，SUDOSCAN检测简单易行，与TNSc评分呈显著负相关，且比TNSc评分用时更短，能够快速有效评估BIPN。

     

    Abstract:
      Objective  To evaluate the use of SUDOSCAN, a peripheral autonomic nerve detection tool, for assessing bortezomib-induced peripheral neuropathy (BIPN).
      Methods  Eighty-six patients with multiple myeloma (MM) from Beijing Chao-yang Hospital, Capital Medical University, between July 2021 and October 2022 were assessed. They received examination of electric skin conductivity (ESC) values with SUDOSCAN. These were compared with the Total Neuropathy Score clinical version (TNSc) and National Cancer Institute Common Toxicity Scale (NCI-CTC) grading. Another 30 patients with no history of tumors or chemotherapy drug exposure were included as controls.
      Results  The ESC value for hands or feet in the experimental group was significantly lower than that of controls (hand: 56.4 μs vs. 76.5 μs, P<0.001; feet: 47.5 μs vs. 78.0 μs, P<0.001). The ESC value was negatively correlated with the TNSc score (r=-0.403, P<0.001); however, it had no significant correlation with the NCI-CTC grade (r=-0.227, P=0.051). There was a significant positive correlation between the NCI-CTC level and the TNSc score (r=0.591, P<0.001). The median evaluation time required by SUDOSCAN was similar to that of NCI-CTC grade (both were 2.4 minutes), and the median evaluation time required by the TNSc score was the longest (13.4 minutes).
      Conclusions  There is no accurate and efficient assessment method for BIPN currently. SUDOSCAN is simple to use and has a significant negative correlation with TNSc scores together with a shorter time. Therefore, SUDOSCAN can evaluate BIPN quickly and effectively.

     

    • HTML全文
    • 参考文献(22)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回